Refractory lymphoid malignancy
Showing 1 - 25 of >10,000
Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma Trial in
Recruiting
- Natural Killer/T-cell Lymphoma
- +2 more
-
Seoul, Kangnamgu, Korea, Republic ofSamsung Medical Center
Sep 22, 2021
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in
Recruiting
- Recurrent Acute Leukemia
- +16 more
- Acetaminophen
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy Trial in Canada, United States (AGS67E)
Completed
- Relapsed Lymphoid Malignancy
- Refractory Lymphoid Malignancy
-
Duarte, California
- +4 more
Nov 27, 2020
Hematologic Malignancy Trial in Tianjin (IMM01)
Terminated
- Hematologic Malignancy
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Sciences and Peking Union Medical Col
May 5, 2023
Tumor, Plasma Cell, Lymphoma Trial in Toulouse (Comprehensive Geriatric Assessment)
Recruiting
- Neoplasm, Plasma Cell
- Lymphoma
- Comprehensive Geriatric Assessment
-
Toulouse, FranceUniversity Hospital Toulouse
Oct 12, 2022
Relapsed Lymphoid Malignancies, Refractory Lymphoid Malignancies Trial in Bentleigh (CN1, 0.5mg/kg and CN401, 400mg, CN1, 1mg/kg
Terminated
- Relapsed Lymphoid Malignancies
- Refractory Lymphoid Malignancies
- CN1, 0.5mg/kg and CN401, 400mg
- +4 more
-
Bentleigh, Victoria, AustraliaMonash Health - Monash Medical Centre
Oct 20, 2022
Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement
Recruiting
- Lymphoma
- +4 more
- Vysis LSI MYC Break Apart Rearrangement Probe Kit
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)
Not yet recruiting
- ALL, Childhood B-Cell
- +2 more
- Tafasitamab
- (no location specified)
Nov 25, 2022
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T
Recruiting
- Non Hodgkin Lymphoma
- +2 more
- Fully human anti CD19 CAR-T Cell Dose
- +2 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- Cyclophosphamide
- +2 more
-
São Paulo, BrazilHospital Israelita Albert Einstein
Jan 20, 2023
Relapsed/Refractory B-cell Malignancies Trial (AC676)
Not yet recruiting
- Relapsed/Refractory B-cell Malignancies
- (no location specified)
Mar 27, 2023
CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)
Recruiting
- CD7+ Acute Leukemia
- CD7+ Lymphoma
- anti-CD7 CAR-T
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Sep 18, 2022
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Decitabine
- +3 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 22, 2023
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +4 more
- Dasatinib
- +5 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 20, 2023
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +2 more
- Best Practice
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Ruxolitinib
- +5 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 16, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte
Recruiting
- Lymphoid Leukemia, Acute
- +2 more
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc
May 24, 2022
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +18 more
- everolimus
- +6 more
-
Scottsdale, Arizona
- +1 more
Sep 28, 2020
International Leukemia Target Board
Not yet recruiting
- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
- Advice
- (no location specified)
Feb 25, 2022
Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)
Recruiting
- Acute T-lymphoblastic Leukemia
- Acute T-lymphoblastic Lymphoma
- CAR-T Cell Infusion
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Trametinib
- +4 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Dec 13, 2022